Coya Therapeutics: Chardan Capital Raises Buy Rating to $14, PT Unchanged

lunes, 16 de marzo de 2026, 3:31 pm ET1 min de lectura
COYA--

Coya Therapeutics: Chardan Capital Raises Buy Rating to $14, PT Unchanged

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios